142 results about "Antibody titer" patented technology

The invention provides a full-automatic indirect immunofluorescence interpretation method and system, a storage medium and a program product, and relates to the technical field of indirect immunofluorescence detection.The method comprises the steps that when identification information of a target sample is obtained, a plurality of sealed antigen slides are placed in slide carrying groove positions of a bearing platform in batches, and the target sample is obtained; driving the bearing platform through the transmission mechanism to sequentially move the plurality of antigen slides to the imaging area, and performing positioning and fixing operation on the antigen slides entering the imaging area by using the positioning and clamping device; sequentially carrying out multi-view scanning on the antigen slides entering the imaging area to obtain multi-view fluorescence images, and splicing the fluorescence images to generate a fluorescence panoramic image; performing feature extraction on the panoramic image, determining a fluorescence karyotype category and a target fluorescence intensity value, and determining an antibody titer according to the category, the intensity value and dilution information; and performing association mapping on the titer, the category and the panoramic image according to the identification information to generate a fluorescence interpretation result.

The invention discloses an influenza C virus HEF protein polyclonal antibody preparation method, which comprises: carrying out signal peptide prediction, antigen epitope screening and hydrophobicity analysis through bioinformatics, constructing a recombinant prokaryotic expression vector pET32a-HEF by using a seamless cloning technology, and efficiently expressing the HEF protein in Escherichia coli to obtain the influenza C virus HEF protein polyclonal antibody. The inclusion body protein yield is improved by optimizing conditions; and purifying by nickel column affinity chromatography to obtain high-purity recombinant protein, emulsifying the high-purity recombinant protein and a Freund's adjuvant, immunizing a Japanese white rabbit, immunizing for three times, and collecting high-titer serum. The method breaks through detection limitation caused by antigen tag concealment in a eukaryotic expression system, the obtained polyclonal antibody is high in specificity, the eukaryotic expression HEF protein can be accurately recognized, and a key tool is provided for ICV virus-like particle identification, vaccine research and development and diagnosis technologies. Compared with a traditional method, the scheme is simple and convenient to operate, low in cost and high in antibody titer, and has remarkable application value.

The invention discloses an application of an AP2-F2 protein polyclonal antibody as a cryptosporidium female gamete positioning tag antibody. The AP2-F2 protein of cryptosporidium parvum is subjected to truncated prokaryotic expression, protein is purified to immunize an ICR mouse, a polyclonal antibody is prepared, ELISA and WB detection of antibody titer are carried out to prove that the polyclonal antibody is effective, then indirect immunofluorescence detection of the antibody is carried out to determine that the polyclonal antibody is located on the female gametes of cryptosporidium parvum, and the polyclonal antibody can be used as a label to locate the female gametes of cryptosporidium parvum. The method plays an important role in localization research of unknown protein of cryptosporidium.

The preparation and evaluation method comprises the following steps: 1, extracting a heavy-chain DNA fragment and a light-chain DNA fragment, carrying out recombinant transformation by using an overlapping PCR method to construct an scFv gene, 2, constructing an expression vector, culturing the expression vector, carrying out sequencing identification to obtain an scFv bacterial solution, recombining the scFv bacterial solution with a mouse Fc fragment, and identifying a sequence to obtain an MN8 bacterial solution, the method comprises the following steps: 1, preparing an MN8 bacterial liquid, 2, extracting the MN8 bacterial liquid, 3, carrying out inoculated culture on the MN8 bacterial liquid to obtain an MN8 genetically engineered antibody bacterial liquid, 4, extracting MN8 genetically engineered antibody bacterial liquid plasmids and carrying out transfection expression purification, and 5, carrying out antibody titer and thermal stability determination on the MN8 genetically engineered antibody. The scFv single-chain antibody obtained by recombination according to the method has the advantages of small molecular weight, high penetrability and the like, the stability and the sensitivity of an immunoassay method of the scolosporins can be improved, and a certain basis is provided for rapid determination of the scolosporins.

The invention discloses an animal serum vaccine detection data processing method and system based on big data, and the method comprises the steps: obtaining a multi-source data set, and sequentially carrying out the data cleaning and time-space alignment of the multi-source data set; key features in the initial multi-source data are extracted, a multi-dimensional feature vector is constructed, and potential association between vaccine effects and environmental factors is mined by using an FP-Growth association mining algorithm; the vaccine effect is predicted based on an XGBoost algorithm, an LSTM neural network model is introduced to analyze the time sequence change trend of antibody titer, and the probability of infection risk is quantified in combination with a Bayesian network; inputting the associated multi-source data into the dynamic prediction model for identification, and outputting a vaccine effect evaluation index; and on the basis of the vaccine effect evaluation index, detecting and judging whether the vaccine batch has recessive infection or not by utilizing an isolated forest. And real-time monitoring and risk early warning of vaccine quality are realized.

This application belongs to the field of biology and discloses a strain of Candida tropicalis, which is classified and named candida tropicalis The deposit number is GDMCC NO: 65030; the deposit date is August 20, 2024, and it is deposited at the Guangdong Provincial Center for Microbiological Culture Collection, with the deposit address being: 5th Floor, Building 59, No. 100, Xianlie Middle Road, Guangzhou. When fermented with this tropical yeast, Astragalus polysaccharide can enhance the immune-enhancing effect of Astragalus polysaccharide, stimulate animals to produce higher antibody titers after immunization, and reduce adverse immune reactions. The present invention also provides an Astragalus polysaccharide fermentation product, a preparation method, and applications.

The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described.

This invention provides a highly pathogenic feline calicivirus strain, its vaccine, and its applications. The highly pathogenic feline calicivirus was isolated from pathogenic material and identified as a highly pathogenic strain, named FCV CC475, with its cDNA sequence shown in SEQ ID NO.1. This strain exhibits strong pathogenicity, causing infected animals to develop symptoms such as fever, paw pad ulcers, and dehydration by day 3 post-infection; the viral load after 5 generations is 10. 9.80 TCID 50 / ml. This strain produces high antibody titers after immunization of cats and rabbits, demonstrating good immunogenicity. Therefore, this highly pathogenic feline calicivirus has broad application prospects in the preparation of feline calicivirus infection vaccines, diagnostic reagents, or therapeutic drugs.

The invention discloses an African swine fever virus vaccine as well as related products and application thereof, and relates to the field of vaccines. The saRNA vaccine of the African swine fever virus provided by the invention adopts an optimized antigen sequence and a saRNA skeleton, and compared with a traditional African swine fever virus vaccine, the saRNA vaccine of the African swine fever virus has the advantages of being early in antibody production period, good in safety, simple in immune procedure, higher in antibody titer and the like.

The application provides a preparation method of polysaccharide vaccine diluent and application to chicken newcastle disease vaccine, and belongs to the technical field of biopharmacy.The application provides a south five canes polysaccharide vaccine diluent and a preparation method thereof, and solves the problems of low uniformity of antibody titer, stress reaction and allergic reaction of the body after inoculation, and influence on the immunization effect of the vaccine caused by the physiological saline or the phosphate buffer solution diluent for diluting the vaccine.The south five canes polysaccharide vaccine diluent can be applied to animal vaccines, including chicken newcastle disease vaccine, and solves the problem that there is no polysaccharide diluent for the chicken newcastle disease vaccine in the prior art.

The invention relates to the field of biological products, and particularly discloses a goose astrovirus, a goose astrovirus egg yolk antibody as well as a preparation method and application of the goose astrovirus egg yolk antibody. The invention relates to a goose astrovirus, which is named as RD240629A, is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No: 46197, and the preservation date is September 23, 2024. The goose astrovirus is named as RD240629A, and the goose astrovirus is named as RD240629A and is preserved in the China General Microbiological Culture Collection Center (CGMCC). The goose astrovirus can be used for preparing the egg yolk antibody for preventing gout of goslings, the egg yolk antibody is good in safety, no local or whole-body adverse reaction caused by antibody injection occurs, infection of the novel goose astrovirus can be effectively prevented and / or treated, and the anti-gout effect is good. The prepared egg yolk antibody is evaluated by adopting antibody titer determination and a challenge protection test, the titer of the egg yolk antibody is not lower than 1: 256, and the egg yolk antibody has a good commercial development prospect.

The present application relates to a kind of cat rhinotracheitis, feline calicivirus disease, cat pancytopenia triple subunit vaccine, preparation method and its application.The present application is expressed antigen protein using CHO cell strain, and synergistic effect is combined molecular adjuvant (IL-2, GM-CSF, CpG) with MF59 nanoemulsion, molecular adjuvant composition is adsorbed on the surface of MF59 nanoemulsion, then embedded in polylactic acid-glycolic acid copolymer microsphere, mixed with triple subunit protein to form vaccine preparation.The vaccine prepared in the present application can stimulate humoral immunity and cellular immunity simultaneously by subcutaneous or intramuscular injection, significantly improve antibody titer and attack protection rate, prolong immune protection period, and reduce injection site adverse reactions.The synergistic effect of protein and molecular adjuvant and MF59 makes the vaccine superior to traditional subunit vaccine in safety, stability and immunological efficacy, and is suitable for high-efficiency prevention of three viral infectious diseases in feline.

The invention discloses design and synthesis of a hapten of cyromazine, development of a cyromazine artificial antigen and a cyromazine antibody, and application of the cyromazine artificial antigen and the cyromazine antibody in the field of food safety rapid detection. The aminocarboxylic acid modified cyromazine hapten product is prepared through the steps of cyromazine hapten design, connecting arm introduction, synthesis, purification and the like. The cyromazine hapten with the structure is coupled with keyhole limpet hemocyanin to form an artificial immune antigen with immunogenicity, and is coupled with chicken ovalbumin to form an artificial competitive antigen. Tests show that the artificial immune antigen has high immunocompetence and can stimulate an animal immune system to generate an anti-cyromazine antibody, and the titer of an immune Blab / c mouse serum antibody is 16000. The IC50 of an enzyme-linked immunosorbent assay (ELISA) detection method established by the cyromazine artificial competitive antigen and the anti-cyromazine antibody is 5.3 [mu] g / L, and the detection sensitivity of an established gold-labeled immunochromatography detection method reaches 50 [mu] g / L.

The invention discloses a halogen modified hapten for enhancing antibody titer and affinity as well as a preparation method and application of the halogen modified hapten, and belongs to the technical field of biochemical engineering. According to the method, an amantadine structure is innovatively and chemically modified, various halogens such as fluorine, chlorine and bromine are introduced, the AMA halogen modified hapten shown in the formula (I) is formed, and the traditional'most similar 'design principle is broken through. Compared with an unmodified hapten, the hapten modified by halogen in the invention has the advantages that the titer of the polyclonal antibody on amantadine can be obviously improved by 3.4-14 times; wherein the haptens A5 and A6 can obviously improve the titer of the monoclonal antibody to amantadine by 3-18 times, and the affinity is improved by 10.8-16.1 times. The invention provides a new thought and a new method for the rational design of the hapten of the small molecule compound and the preparation of the high-affinity antibody, and the related halogen modification type and quantity strategy can also provide valuable reference for the design of the hapten of other small molecule compounds.

The invention belongs to the technical field of nano biological materials, and particularly relates to a preparation method of cell membrane coated nanoparticles based on solvent equilibrium and sulfydryl anchoring. According to the method, sulfydryl-containing lipid is doped into a membrane system, so that the sulfydryl-containing lipid and the surface of a substrate form a covalent anchor bond to enhance the membrane-substrate binding force, and a small amount of organic solvent is added to improve the fluidity of the lipid and promote spontaneous fusion and uniform spreading of a membrane layer on the surfaces of particles. And centrifuging and washing to obtain the cell membrane nanoparticles with completely coated surfaces. According to the method, high-energy ultrasonic or extrusion treatment is not needed, stable coating can be realized on the premise of maintaining complete composition of membrane protein and lipid, and the adhesion stability of a membrane layer in a high-salt and shearing environment is remarkably improved. The method is suitable for various nano substrates and different morphological structures, and the obtained particles show higher antibody titer and excellent safety in an anti-alpha-hemolysin vaccine model. The invention provides a mild and efficient bionic nano material construction strategy with wide applicability.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The application discloses a HtsA-SLOdm fusion protein and application thereof in preparation of a group A streptococcus vaccine. The HtsA-SLOdm fusion protein is obtained by fusing and recombining a heme transport lipoprotein (HtsA) and a streptolysin protein containing a double-mutation site (SLOdm), can induce production of HtsA protein and SLOdm protein specific IgG antibodies in serum, has strong immunogenicity, can induce high-level IgG1 and IgG2a antibody titers, and the humoral immune response in inducing production of SLOdm protein specific IgG antibodies in serum is stronger than that of a single protein. In addition, the HtsA-SLOdm fusion protein can promote skin wound healing of mice, reduce bacterial content and inflammatory response at a skin infection site of the mice, accelerate wound healing, has almost no hemolytic activity, has high safety, and can be used for preparing a group A streptococcus vaccine.

The present invention relates to the field of immunoassay technology and provides a bifenthrin hapten, antigen, antibody, preparation method, and application thereof. The bifenthrin hapten provided by the present invention completely retains the molecular structure of bifenthrin. After coupling with a carrier protein, the immunogenicity of the resulting antigen is significantly improved, and the prepared antibody has stronger specificity and higher sensitivity. The results of the examples show that the bifenthrin hapten provided by the present invention is coupled with a carrier protein, and the resulting antigen, after injection into mice for immunization, produces an antibody titer of 1×10 4 , half inhibitory concentration (IC 50 ) is about 20ppb, and the minimum detection limit of colloidal gold for bifenthrin in dry tobacco leaf samples is about 1.25μg / g.

The application discloses a phosphoric acid modified protein or polypeptide, a preparation method thereof and application thereof in vaccines, and belongs to the field of protein phosphoric acid modification. The preparation method of the phosphoric acid modified protein or polypeptide is as follows: a compound containing an aldehyde group and a phosphate group is subjected to nucleophilic reaction with a protein or polypeptide to form a Schiff base; a reducing agent is used to reduce the Schiff base, and after post-treatment, the phosphoric acid modified protein or polypeptide is obtained. After the phosphoric acid modified protein product prepared by the method is prepared into a vaccine with an aluminum hydroxide adjuvant and mice are immunized, the antibody titer is significantly increased. This is of great significance for increasing the immune effect, reducing the inoculation dose, saving the antigen amount and improving the immune response of some people or in specific conditions.

The invention discloses an instantaneous transfection method for high-yield CHO-K1 (CHO-K1) by taking linearized PEI (Polyetherimide) as a transfection reagent. The antibody titer reaches about 1g / L within 10 days by replacing a culture medium, zero incubation of a compound, a specific DNA proportion and temperature regulation, the dosage of an expression vector is remarkably reduced, the research and development period is shortened, and the method is suitable for early research and development of antibody drugs and sample preparation.

The invention belongs to the field of medicinal chemistry and pharmacology, and relates to application of a novel glycolipid TLR2 agonist 13-C in preparation of vaccine adjuvants and anti-tumor treatment. The compound is excellent in human TLR2 agonist activity, EC50 reaches 2.2 nM, and the compound is simple in structure, easy to prepare and excellent in solubility and has industrial application potential. In a B16-OVA tumor model, the antibody induction capacity of the compound is superior to that of a positive control drug Diprovocim, and the anti-tumor activity of the compound is more remarkable; in addition, PD-L1 expression of tumor tissue can be effectively down-regulated, and a synergistic anti-tumor effect is generated with a PD-L1 monoclonal antibody Atezolizumab. Besides, 13-C and a vaccine adjuvant QS-21 are combined for use, so that a synergistic enhancement effect is achieved, the antibody titer induced by a vaccine can be remarkably improved, antibody subtypes are enriched, meanwhile, cellular immunity and humoral immunity response of an organism are stimulated, and the effect of dual immune activation is achieved.

Provided are compositions and methods for reducing pre-existing antibodies against viral vector or gene-editing related proteins. The compositions showed reduction in various antibody titers by administration of a liposome composition complexed with a protein or fragment thereof of a viral vector. The liposomes comprise phosphatidylcholine and phosphatidylserine, wherein some or all of the PS is present as lyso-PS. The compositions and methods can be used in conjunction with gene therapy and nucleic acid based vector based vaccinations and therapeutics.

The present invention discloses a rabies inactivated vaccine diluent and its preparation method and application, belonging to the technical field of vaccine diluents. The invention provides an inactivated vaccine diluent to solve the technical problems of low antibody titer, long production time and short antibody maintenance time after animal inactivated vaccine immunization. The invention provides a rabies inactivated vaccine diluent, which is composed of the following components: phosphate buffer, MONTANIDE TM GEL 02 PR adjuvant, canine interferon, and ricin B chain protein. This diluent can significantly increase the rabies neutralizing antibody titer after rabies inactivated vaccine administration.

The invention relates to the technical field of antibody titer digitization analysis, in particular to a brucellosis antibody titer digitization analysis system based on a spectrophotometric method.According to the brucellosis antibody titer digitization analysis system, a full-time reaction kinetics absorbance curve is obtained through a data acquisition module; a signal decomposition module is utilized to decouple the signal into a low-frequency trend component and a high-frequency detail component; further identifying a reaction kinetics phase state through a low-frequency trend analysis module to lock an effective reaction interval and generate first-dimension analysis data, and controlling a high-frequency detail analysis module to generate second-dimension analysis data by taking the first-dimension analysis data as a time domain gating basis; finally, the comprehensive evaluation module constructs a coupling weight model based on the reaction kinetics phase state, and fuses the two-dimensional data to generate a comprehensive antibody activity evaluation value; according to the process, a self-adaptive analysis mechanism conforming to a reaction evolution rule is constructed, and accurate determination of the titer of the antibody is realized.

This invention provides a method for detecting AAV antibody titers, belonging to the field of biomedical technology, comprising: S1 preparing serum-free AAV vectors with different MOI values; preparing a mixture containing different volumes of test serum samples and AAV vectors with known MOI values ​​for co-incubation; S2: adding plasmids containing the CRISPR-Cas9 gene editing system to electroporation buffer, performing electroporation on a known number of cells, adding the serum-free AAV vectors and mixture from step S1 to the electroporated cells respectively, and detecting the expression efficiency of the reporter gene after electroporation; S3: calculating the AAV antibody titer in the test serum sample based on the detection results. The main advantage of this invention is that it can display AAV antibody titers digitally and quantitatively, facilitating understanding and communication, and obtaining stable and reliable results using different cell lines and different AAV transduction doses. This method is easy to standardize and validate, saving time, effort, and detection costs compared to traditional methods, and directly reflects antibody neutralizing activity.

The preparation and evaluation method comprises the following steps: 1, extracting a heavy-chain DNA fragment and a light-chain DNA fragment, carrying out recombinant transformation by using an overlapping PCR method to construct an scFv gene, 2, constructing an expression vector, culturing the expression vector, carrying out sequencing identification to obtain an scFv bacterial solution, recombining the scFv bacterial solution with a mouse Fc fragment, and identifying a sequence to obtain an MN8 bacterial solution, the method comprises the following steps: 1, preparing an MN8 bacterial liquid, 2, extracting the MN8 bacterial liquid, 3, carrying out inoculated culture on the MN8 bacterial liquid to obtain an MN8 genetically engineered antibody bacterial liquid, 4, extracting MN8 genetically engineered antibody bacterial liquid plasmids and carrying out transfection expression purification, and 5, carrying out antibody titer and thermal stability determination on the MN8 genetically engineered antibody. The scFv single-chain antibody obtained by recombination according to the method has the advantages of small molecular weight, high penetrability and the like, the stability and the sensitivity of an immunoassay method of the scolosporins can be improved, and a certain basis is provided for rapid determination of the scolosporins.

This invention discloses an enzyme-linked immunosorbent assay (ELISA) kit for detecting benzo[a]pyrene in edible oil, kitchen fumes, and vehicle exhaust. The kit includes: a sample reconstitution solution, an enzyme conjugate / antibody diluent, a standard / sample diluent, a benzo[a]pyrene standard, a benzo[a]pyrene-specific mouse monoclonal antibody, an enzyme conjugate, an ELISA plate coated with benzo[a]pyrene antigen, a chromogenic solution, a stop solution, and a washing solution. This invention also discloses a method for detecting benzo[a]pyrene in edible oil, kitchen fumes, and vehicle exhaust using the kit, including sample pretreatment, ELISA detection, and result processing and analysis. The sample reconstitution solution, enzyme conjugate / antibody diluent, and standard / sample diluent provided by this invention overcome the solubility problem of benzo[a]pyrene in edible oil, kitchen fumes, and vehicle exhaust while maintaining antibody sensitivity, and can also significantly improve antibody titer, thus possessing significant value for widespread application.

The present invention relates to the technical field of vaccine preparation, and in particular to an ASP-ETX fusion protein and a Clostridium perfringens epsilon toxin nanoparticle vaccine and a preparation method thereof. The ASP-ETX fusion protein of the present invention comprises Clostridium perfringens epsilon toxin and an activation-related secretory protein; the amino acid sequence of the ASP-ETX fusion protein is shown in SEQ ID NO.1. The Clostridium perfringens epsilon toxin nanoparticle vaccine is obtained by co-incubating the ASP-ETX fusion protein with cell membrane-wrapped nanoparticles. The vaccine exhibits excellent biosafety in both cells and animals, and induces the production of up to 10 5 ETX-specific antibodies with a neutralizing antibody titer of up to 64 can protect mice against 100×LD 50 GST-ETX toxin attack has great potential to replace traditional ETX vaccines.

The purpose of the present invention is to provide, as a platform technique that may serve as preparation for pandemics, a rapid antibody production technique in which a non-human animal having a human antibody gene is used. More specifically, the purpose of the present invention is to provide an immunization method with which it is possible to induce, in a short period of time, a high antigen-binding ability of an antibody or a high antibody titer of an antiserum, and a method for producing a human antibody / antiserum with which it is possible to rapidly produce a wide range of neutralizing antibodies.　(1) An immunization method for rapidly inducing a human monoclonal antibody having a high ability to bind to a desired antigen or a human polyclonal antibody having a high antibody titer, the method comprising a step for immunizing a non-human animal a plurality of times with a desired antigen or a nucleic acid encoding the antigen within 30 days from the first immunization, the non-human animal having a human antibody gene or locus, and the non-human animal being such that an endogenous gene or locus of the non-human animal corresponding to the human antibody gene or locus is disrupted or deleted, or mutated so as to result in a loss of expression or low expression. (2) A method for producing a human antibody against a desired antigen using a non-human animal, the method comprising: an immunization step for immunizing the non-human animal with the antigen or a nucleic acid encoding the antigen; a human immunoglobulin-positive B cell isolation step for isolating B cells that are human immunoglobulin-positive from a tissue of the immunized non-human animal; an antibody base sequence acquisition step for acquiring the base sequences of antibody light-chain mRNA-derived cDNA and antibody heavy-chain mRNA-derived cDNA prepared from the isolated B cells; and an antibody production step for producing an antibody on the basis of the acquired antibody base sequence, the non-h